Venus Receives Marketing Authorization for its Generic Cancer Drugs
Venus has been working on target-based drug delivery for cancer treatment and diagnostics.
The company has recently received marketing authorizations for its cancer drugs from Uzbekistan and Palestine. It has received marketing approval for Carboplatin in Uzbekistan and Docetaxel and Irinotecan in Palestine.
With over 800 marketing authorizations worldwide, this approval marks a significant step for the company as it aligns with its overall goal of meeting the unmet global needs in the community. The drugs are expected to launch in the next financial year in Uzbekistan and Palestine, countries with limited access to quality healthcare supplies.
Oncology Research at Venus Medicine Research Center (VMRC) focuses on target-based nanotechnology Stealth Targeted Nanodelivery (STN) and the novel concept of Drug Protein Polymer Conjugate (DPPC) to deliver targeted drug delivery for cancer treatments.
The research team at VMRC is working proactively towards providing early, cost-effective, easy-to-use & implement solutions for cancer. Cancer is the second-most common cause of death globally, and one of the leading causes of morbidity. The oncology space has been the focal point of the company's research segment. Hence, this makes a crucial achievement for Venus, for being able to deliver such medical requirements to other countries.
The company has a reputation for manufacturing high-quality products for oncology, carbapenems, and cephalosporins. Its production facilities, while following EU-GMP norms, are contributing substantially to the oncology segment across the globe through a wide array of products, including Docetaxel, Paclitaxel, Gemcitabine, Oxaliplatin, Bortezomib, and Pemetrexed.